Literature DB >> 21439328

Cytomegalovirus reactivation in critically ill immunocompetent hosts: a decade of progress and remaining challenges.

Charles H Cook1, Joanne Trgovcich.   

Abstract

Human cytomegalovirus (HCMV) is an undisputed pathogen in humans with severe immune compromise, which has historically been thought to carry little consequence in immunocompetent hosts. During the past decade, however, accumulating data suggest that significant numbers of immunocompetent humans reactivate HCMV during critical illness, and that these reactivation episodes are associated with worsened outcomes. Because most people are infected with this ubiquitous virus by adulthood, confirming pathogenicity has now become a clinical priority. In this article, we will review the incidence and implications of reactivation, the relevant immune responses and reactivation triggers relevant to the immunocompetent host. We will summarize the progress made during the past ten years, outline the work ongoing in this field, and identify the major gaps remaining in our emerging understanding of this phenomenon.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21439328      PMCID: PMC3129598          DOI: 10.1016/j.antiviral.2011.03.179

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  145 in total

1.  The dynamics of mouse cytomegalovirus-specific CD4 T cell responses during acute and latent infection.

Authors:  Senta M Walton; Philippe Wyrsch; Michael W Munks; Albert Zimmermann; Hartmut Hengel; Ann B Hill; Annette Oxenius
Journal:  J Immunol       Date:  2008-07-15       Impact factor: 5.422

2.  Cytomegalovirus reactivation in "immunocompetent" patients: a call for scientific prophylaxis.

Authors:  Charles H Cook
Journal:  J Infect Dis       Date:  2007-10-01       Impact factor: 5.226

3.  Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study.

Authors:  Drew J Winston; Jo-Anne H Young; Vinod Pullarkat; Genovefa A Papanicolaou; Ravi Vij; Estil Vance; George J Alangaden; Roy F Chemaly; Finn Petersen; Nelson Chao; Jared Klein; Kellie Sprague; Stephen A Villano; Michael Boeckh
Journal:  Blood       Date:  2008-02-19       Impact factor: 22.113

Review 4.  Clinical relevance of cytomegalovirus infection in patients with disorders of the immune system.

Authors:  C Steininger
Journal:  Clin Microbiol Infect       Date:  2007-10       Impact factor: 8.067

5.  Cellular immunity and active human cytomegalovirus infection in patients with septic shock.

Authors:  Lutz von Muller; Anke Klemm; Nilgun Durmus; Manfred Weiss; Heide Suger-Wiedeck; Marion Schneider; Walter Hampl; Thomas Mertens
Journal:  J Infect Dis       Date:  2007-10-01       Impact factor: 5.226

Review 6.  Human CMV vaccine trials: what if CMV caused a rash?

Authors:  Stuart P Adler
Journal:  J Clin Virol       Date:  2007-12-21       Impact factor: 3.168

Review 7.  Modulation of natural killer cells by human cytomegalovirus.

Authors:  Gavin W G Wilkinson; Peter Tomasec; Richard J Stanton; Melanie Armstrong; Virginie Prod'homme; Rebecca Aicheler; Brian P McSharry; Carole R Rickards; Daniel Cochrane; Sian Llewellyn-Lacey; Eddie C Y Wang; Cora A Griffin; Andrew J Davison
Journal:  J Clin Virol       Date:  2008-03       Impact factor: 3.168

8.  Subdominant CD8 T-cell epitopes account for protection against cytomegalovirus independent of immunodomination.

Authors:  Rafaela Holtappels; Christian O Simon; Michael W Munks; Doris Thomas; Petra Deegen; Birgit Kühnapfel; Torsten Däubner; Simone F Emde; Jürgen Podlech; Natascha K A Grzimek; Silke A Oehrlein-Karpi; Ann B Hill; Matthias J Reddehase
Journal:  J Virol       Date:  2008-03-26       Impact factor: 5.103

Review 9.  Human cytomegalovirus infection and antiviral immunity in septic patients without canonical immunosuppression.

Authors:  Lutz von Müller; Thomas Mertens
Journal:  Med Microbiol Immunol       Date:  2008-03-08       Impact factor: 3.402

Review 10.  Murine cytomegalovirus regulation of NKG2D ligands.

Authors:  Tihana Lenac; Jurica Arapović; Luka Traven; Astrid Krmpotić; Stipan Jonjić
Journal:  Med Microbiol Immunol       Date:  2008-02-08       Impact factor: 3.402

View more
  22 in total

1.  Activation of human herpesvirus replication by apoptosis.

Authors:  Alka Prasad; Jill Remick; Steven L Zeichner
Journal:  J Virol       Date:  2013-07-24       Impact factor: 5.103

Review 2.  Impact of cytomegalovirus load on host response to sepsis.

Authors:  Thomas Marandu; Michael Dombek; Charles H Cook
Journal:  Med Microbiol Immunol       Date:  2019-04-11       Impact factor: 3.402

Review 3.  Resistant pathogens, fungi, and viruses.

Authors:  Christopher A Guidry; Sara A Mansfield; Robert G Sawyer; Charles H Cook
Journal:  Surg Clin North Am       Date:  2014-10-03       Impact factor: 2.741

4.  Xenotransplantation: Progress Along Paths Uncertain from Models to Application.

Authors:  Jeffrey L Platt; Marilia Cascalho; Jorge A Piedrahita
Journal:  ILAR J       Date:  2018-12-31

Review 5.  The immunological underpinnings of vaccinations to prevent cytomegalovirus disease.

Authors:  A Louise McCormick; Edward S Mocarski
Journal:  Cell Mol Immunol       Date:  2014-12-29       Impact factor: 11.530

6.  Rapid discrimination of MHC class I and killer cell lectin-like receptor allele variants by high-resolution melt analysis.

Authors:  Alyssa Lundgren; Sharon Kim; Michael D Stadnisky; Michael G Brown
Journal:  Immunogenetics       Date:  2012-07-01       Impact factor: 2.846

7.  CMV seropositivity is a potential novel risk factor for severe COVID-19 in non-geriatric patients.

Authors:  Simone Weber; Victoria Kehl; Johanna Erber; Karolin I Wagner; Ana-Marija Jetzlsperger; Teresa Burrell; Kilian Schober; Philipp Schommers; Max Augustin; Claudia S Crowell; Markus Gerhard; Christof Winter; Andreas Moosmann; Christoph D Spinner; Ulrike Protzer; Dieter Hoffmann; Elvira D'Ippolito; Dirk H Busch
Journal:  PLoS One       Date:  2022-05-25       Impact factor: 3.752

Review 8.  Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy.

Authors:  Richard S Hotchkiss; Guillaume Monneret; Didier Payen
Journal:  Nat Rev Immunol       Date:  2013-11-15       Impact factor: 53.106

9.  Dual analysis of the murine cytomegalovirus and host cell transcriptomes reveal new aspects of the virus-host cell interface.

Authors:  Vanda Juranic Lisnic; Marina Babic Cac; Berislav Lisnic; Tihana Trsan; Adam Mefferd; Chitrangada Das Mukhopadhyay; Charles H Cook; Stipan Jonjic; Joanne Trgovcich
Journal:  PLoS Pathog       Date:  2013-09-26       Impact factor: 6.823

Review 10.  Dendritic cell biology in human cytomegalovirus infection and the clinical consequences for host immunity and pathology.

Authors:  Sara Gredmark-Russ; Cecilia Söderberg-Nauclér
Journal:  Virulence       Date:  2012-10-17       Impact factor: 5.882

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.